How to determine capmatinib discontinuation?

Capmatinib (Capmatinib) is a targeted therapy for patients with non-small cell lung cancer (NSCLC) carrying MET exon 14 skipping mutations. Its treatment cycle is not fixed, but can be flexibly adjusted based on the patient's treatment response and tolerance to side effects. While patients are receiving capmatinib treatment, they will undergo regular medical evaluation so that doctors can adjust treatment strategies in a timely manner.

Treatment with capmatinib aims to control the disease and slow down tumor growth and metastasis. For patients who respond well to treatment and whose disease progresses slowly, doctors may recommend continued medication to maintain a stable condition. However, the specific timing and method of drug discontinuation need to be comprehensively considered based on the patient's specific condition, tumor size, overall health status, and whether drug resistance has occurred.

The clinical decision to discontinue a drug involves many aspects, including whether the patient develops drug resistance, serious side effects or other unacceptable adverse reactions. After long-term use of capmatinib, MET mutated tumor cells may become resistant to the drug, leading to the emergence of drug resistance. At this point, your doctor may consider discontinuing the medication and switching to another medication or treatment. Therefore, patients should never decide to stop taking medication on their own and must do so under the guidance of a doctor.

Progression-free survival (PFS) is an important indicator to measure the effect of capmatinib treatment. If the patient's tumor remains stable or shrinks during treatment and he or she does not experience serious side effects, treatment may continue. Once a patient's condition progresses, the doctor may recommend stopping the medication and exploring other treatment options. Patients should maintain close communication with their doctors, undergo regular examinations, evaluate the efficacy and side effects, and jointly decide whether to continue taking the medication.

After treatment, patients still need to have regular check-ups to monitor changes in their condition. After discontinuing medication, some patients may experience relapse or disease rebound, so doctors usually recommend continued monitoring measures such as imaging examinations and biomarker testing. In addition, patients may also want to consider other medications or treatments to prevent the cancer from coming back.

xa0

Reference materials

FDA Capmatinib Approval Information -

https://www.fda.gov/drugs/drug-approvals-and-databases/tabrecta-capmatinib